Inflammatory mediators in sepsis: rationale for extracorporeal therapies?

This publication has 114 references indexed in Scilit:

• Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.
  The Journal of Experimental Medicine, 1993
• American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference
  Critical Care Medicine, 1992
• Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro
  Immunology Today, 1991
• The Cardiovascular Response of Normal Humans to the Administration of Endotoxin
  New England Journal of Medicine, 1989
• Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxofylline
  Biochemical and Biophysical Research Communications, 1988
• Detection of Circulating Tumor Necrosis Factor after Endotoxin Administration
  New England Journal of Medicine, 1988
• Effect of High-Dose Glucocorticoid Therapy on Mortality in Patients with Clinical Signs of Systemic Sepsis
  New England Journal of Medicine, 1987
• A Controlled Clinical Trial of High-Dose Methylprednisolone in the Treatment of Severe Sepsis and Septic Shock
  New England Journal of Medicine, 1987
• Cachectin: More Than a Tumor Necrosis Factor
  New England Journal of Medicine, 1987
• Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a MutantEscherichia coli
  New England Journal of Medicine, 1982